SCHEMBL3430232

SCHEMBL3430232

CC(C)(C)[Si](C)(C)OCc1c(F)cccc1-c1ccc2nc(-c3nc4ccccc4s3)cn2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.39
ABL1 P00519 3/20 0.37
F2RL3 Q96RI0 4/20 0.36
TNF P01375 1/20 0.35
NOD1 Q9Y239 1/20 0.35
NR4A2 P43354 2/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPT P10636 3/20 0.33
KDM4E B2RXH2 2/20 0.33
PKM P14618 1/20 0.33
P2RY6 Q15077 1/20 0.33
POLB P06746 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
S1PR2 O95136 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063966 0.84 ALDH1A3 (0.47) LRRK2ABL1NR4A2NPC1RAB9A
SCHEMBL3409257 0.82 NR4A2 (0.49) LRRK2ABL1NR4A2NPC1RAB9A
SCHEMBL2064094 0.82 NR4A2 (0.54) LRRK2ABL1NR4A2NPC1RAB9A
SCHEMBL2064623 0.80 LRRK2 (0.44) LRRK2ABL1NR4A2
SCHEMBL3430238 0.77 F2RL3 (0.39) LRRK2ABL1F2RL3TNFNOD1
SCHEMBL3426792 0.74 NR4A2 (0.64) F2RL3NR4A2NPC1RAB9ASMN1; SMN2
SCHEMBL219947 0.73 L3MBTL1 (0.39) NR4A2NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL2063436 0.72 NR4A2 (0.53) NR4A2NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL10106660 0.71 NR4A2 (0.46) LRRK2ABL1NR4A2NPC1RAB9A
SCHEMBL2064143 0.68 NR4A2 (0.50) LRRK2ABL1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP disclosed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN LRRK2 912/4885ABL1 1/4885F2RL3 2130/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN LRRK2 912/4885ABL1 1/4885F2RL3 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.